Analyst: Lundbeck has gained advantage
Analyst Søren Løntoft Hansen of Sydbank believes results from a new study with Lundbeck’s antidepressant Brintellix gives the company a competitive edge.
by Viktor Brandt Kærgaard
A new study has shown Lundbeck’s Brintellix to improve the cognitive ability of patients with major depression disorder. Pharmaceutical sector analyst in Sydbank, Søren Løntoft Hansen, believes it puts the Danish drug group in a highly favorable position.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck CEO wants to match rival's achievements
For abonnenter
Diamond in the rough in Lundbeck’s pipeline
For abonnenter
R&D chief: Brintellix data are highly significant
For abonnenter
